STAT3 and hepatocellular carcinoma: Sorafenib, which inhibits STAT3 and phosphorylates TGF-β that are both up-regulated in EMT, is being considered as a potential therapeutic agent in HCC, but adverse events and resistance limited the therapeutic effectiveness (4).